Skip to main content
    D

    DBV Technologies (DBVT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.27
    -0.74 (-6.76%)

    Market Cap: $692.19M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    DBV Technologies (DBVT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to DBV Technologies are Vir Biotechnology (VIR), 4D Molecular Therapeutics (FDMT) and Valneva SE ADR (VALN). By market cap, DBV Technologies ranks 10th of the 13 companies on this page; Vir Biotechnology (VIR) is the largest at $1.71B.

    Peer Comparison

    DBVT's ROIC of -130.3% is below the peer median of -45.3%, and its revenue growth of -42.9% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    DBV Technologies (DBVT)$692.19MN/AN/A0.0%-130.3%-42.9%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    4D Molecular Therapeutics Inc (FDMT)$689.52MN/A8.5x-208.6%-46.4%4506.0%0.00%
    Valneva SE ADR (VALN)$538.42MN/A3.2x-110.3%-44.2%-27.7%0.00%
    CureVac NV (CVAC)$1.05BN/A1.8x182.1%N/A-89.0%0.00%
    Nuvectis Pharma Inc (NVCT)$696.03MN/AN/A0.0%N/A0.0%0.00%
    Immatics NV (IMTX)$972.99MN/A17.7x0.0%N/A33.5%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Corvus Pharmaceuticals Inc (CRVS)$897.52MN/AN/A0.0%N/A0.0%0.00%
    Solid Biosciences LLC (SLDB)$763.42MN/AN/A0.0%N/A-100.0%0.00%
    Vor Biopharma Inc (VOR)$1.19BN/AN/A0.0%N/A0.0%0.00%
    Inventiva Sa (IVA)$879.90MN/A133.4x0.0%-327.7%-76.7%0.00%
    Peer median$882.04M95.1x8.4x0.0%-45.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to DBV Technologies, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors
    4D Molecular Therapeutics Inc (FDMT)
    4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors.
    FDMT competitors
    Valneva SE ADR (VALN)
    Valneva SE, a company specialized in vaccines, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet...
    VALN competitors
    CureVac NV (CVAC)
    CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA).
    Nuvectis Pharma Inc (NVCT)
    Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer.
    NVCT competitors
    Immatics NV (IMTX)
    Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies...
    IMTX competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Corvus Pharmaceuticals Inc (CRVS)
    Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
    CRVS competitors
    Solid Biosciences LLC (SLDB)
    Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States.
    SLDB competitors
    Vor Biopharma Inc (VOR)
    Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients.
    VOR competitors
    Inventiva Sa (IVA)
    Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic...

    Frequently Asked Questions About DBVT

    Who are DBV Technologies' main competitors?

    The companies most similar to DBV Technologies include Vir Biotechnology (VIR), 4D Molecular Therapeutics (FDMT), Valneva SE ADR (VALN), CureVac NV (CVAC) and Nuvectis Pharma (NVCT), listed from the closest match.

    Who is DBV Technologies' biggest competitor?

    Vir Biotechnology (VIR) is both the largest of the similar companies at $1.71B and the closest match by business profile, size, sector and industry.

    How does DBVT stock compare with its competitors?

    DBVT's net margin is 0.0% against a peer median of 0.0%.

    Which of DBV Technologies' competitors pays a higher dividend?

    DBV Technologies pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is DBV Technologies bigger than its competitors?

    No. DBV Technologies is 10th by market cap among the 13 companies on this page; the largest is Vir Biotechnology (VIR) at $1.71B.